Article January 26, 2021
Kurt Glitzenstein Featured on Cover of Metropolitan Corporate Counsel
- Person title
Litigation Practice Group Leader Kurt Glitzenstein is featured on the cover of the November issue of Metropolitan Corporate Counsel magazine. In the article, Kurt discusses his work, and what has gotten Fish ranked the #1 Patent Litigation Firm by the publication for 13 years in a row.
“Our sweet spot is high-stakes cases where complicated technology, complicated facts and complicated law all intersect.”
To read the entire article, click on the magazine cover to the left.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Q&A January 21, 2020
Q&A with Kurt Glitzenstein for Corporate Counsel Business Journal, "Mastering the Art of Pricing in Complex Litigation"
Q&A March 18, 2019
Q&A with Kurt Glitzenstein for Corporate Counsel Business Journal
Q&A June 5, 2017
Q&A with Kurt Glitzenstein: Patently Powerful
Blog December 4, 2023
Amended FRE 702 on Expert Testimony Effective December 1, 2023
Blog December 1, 2023
ITC Monthly Wrap-Up: November 2023
Blog November 27, 2023
Minnesota Patent Litigation Wrap-Up: Q3 2023
Blog November 15, 2023
ITC Monthly Wrap-Up: October 2023
Blog November 9, 2023
Legal Alert: FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book
Blog November 3, 2023
District of Delaware Finds Allergan Patents Invalid for Lack of Written Description and Obviousness-Type Double Patenting in Allergan v. MSN Labs
Blog October 31, 2023
Texas Patent Litigation Monthly Wrap-Up: October 2023
Blog October 30, 2023
District of Delaware Finds Non-Orange Book-Listed Patents Subject to the Same Pleading Standard as Listed Patents in ANDA Infringement Suit
Blog October 11, 2023
ITC Monthly Wrap-Up: September 2023
Blog September 25, 2023
Federal Circuit Evaluates Enablement for Antibody Claims for the First Time Since Amgen v. Sanofi in Baxalta Inc. et al. v. Genentech, Inc.